GU Cancers 2020 | JAVELIN Renal 101: DepOR & outcomes in RCC
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Martin Voss, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the depth of response (DepOR) analysis from the JAVELIN Renal 101 trial (NCT02684006), and the correlation with clinical outcomes in renal cell cancer (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up